Marcin Czerwinski/LinkedIn;
Radoslaw Kaczmarek/LinkedIn
Mar 28, 2026, 17:01
Marcin Czerwinski: Neutralizing Anti-AAV Antibodies in Hemophilia B Gene Therapy
Marcin Czerwinski, Professor at Hirszfeld Institute of Immunology and Experimental Therapy, shared a post on LinkedIn about a recent article by Radoslaw Kaczmarek, adding:
“Radoslaw (Radek) Kaczmarek just wrote a great commentary about neutralizing anti-AAV antibodies (NAbs) in hemophilia B therapy that can block transduction, thereby abolishing efficacy.
It seems that this is not the case…”
Title: Hemophilia B gene therapy: a NAb-solute barrier overcome by AAV5
Author: Radoslaw Kaczmarek
Read the Full Article on RPTH Journal

Stay updated with Hemostasis Today.
-
Nov 18, 2026, 14:13Alvin Katumba: Sickle Cell Disease Research Recognised With a 2026 ASH Abstract Achievement Award
-
Nov 18, 2026, 13:34Vincenzo De Angelis: Strengthening Plasma Management and Quality Control in Eastern Europe
-
Nov 18, 2026, 13:34Standardizing Bleeding Outcome Assessment in Hemophilia Clinical Trials – JTH
-
Nov 18, 2026, 13:34Nicolas Gendron: Towards Sustainable Anticoagulation
-
Nov 18, 2026, 13:33Breaking the Silence on Women and Girls with Bleeding Disorders – EHC
-
Nov 18, 2026, 13:32Maria Elisa Mancuso: Next-Generation Protein Therapies in Hemophilia
-
Nov 18, 2026, 13:25Maia Meier: Advocating for Women and Girls with Bleeding Disorders
-
Nov 18, 2026, 13:19Sjoerd Fabian Koopman: Exploring Tissue Distribution of Extended Half-Life Factor IX Concentrates
-
Nov 18, 2026, 13:16Ifeanyichukwu Ifechidere: Choosing Between Clot-Based and Chromogenic Coagulation Assays